Original language | English (US) |
---|---|
Pages (from-to) | 16-19 |
Number of pages | 4 |
Journal | Nature biotechnology |
Volume | 30 |
Issue number | 1 |
DOIs |
|
State | Published - Jan 2012 |
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
- Applied Microbiology and Biotechnology
- Molecular Medicine
- Biomedical Engineering
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The NIH's role in accelerating translational sciences. / Reed, John C.; White, E. Lucile; Aub́, Jeffrey; Lindsley, Craig; Li, Min; Sklar, Larry; Schreiber, Stuart.
In: Nature biotechnology, Vol. 30, No. 1, 01.2012, p. 16-19.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - The NIH's role in accelerating translational sciences
AU - Reed, John C.
AU - White, E. Lucile
AU - Aub́, Jeffrey
AU - Lindsley, Craig
AU - Li, Min
AU - Sklar, Larry
AU - Schreiber, Stuart
N1 - Funding Information: The proposed plan for NCATS, which was devised with input from a broad spectrum of knowledgeable stakeholders1, aims to solidify and expand NIH’s commitment to improving the efficiency with which its investment in basic research is translated into improvements in human health. Nearly all of the programs slated to move into NCATS are already funded by NIH2, through the NIH Center for Research Resources, the NIH Common Fund or the Office of the Director. Importantly, much of what NCATS will support provides a basic infrastructure for America’s nonprofit life sciences research community to enable translation of basic research into clinical impact, including such programs as the (i) Clinical and Translational Science Awards (CTSA; https://www.ctsacentral. org/), which provide a broad spectrum of services and organizational capabilities for fostering translational and clinical research at 60 of the nation’s medical schools; (ii) the Molecular Libraries Program (MLP), which provides essential infrastructure for small-molecule drug discovery, making sophisticated services available in assay development, high-throughput screening, large chemical libraries, cheminformatics and medicinal chemistry (http://mli.nih.gov/mli/); and (iii) Therapeutics for Rare & Neglected Diseases, devoted to nurturing promising therapies for rare and neglected diseases through preclinical development and into clinical testing (http://trnd.nih.gov/). Here we describe what we see as the feasibility, opportunities, possible pitfalls and potential impact of NCATS. Copyright: Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/1
Y1 - 2012/1
UR - http://www.scopus.com/inward/record.url?scp=84862912729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862912729&partnerID=8YFLogxK
U2 - 10.1038/nbt.2087
DO - 10.1038/nbt.2087
M3 - Comment/debate
C2 - 22231085
AN - SCOPUS:84862912729
VL - 30
SP - 16
EP - 19
JO - Biotechnology
JF - Biotechnology
SN - 1087-0156
IS - 1
ER -